| 0.895 -0.315 (-26.03%) | 09-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.4 |
1-year : | 1.72 |
| Resists | First : | 1.19 |
Second : | 1.48 |
| Pivot price | 0.97 |
|||
| Supports | First : | 0.74 |
Second : | 0.61 |
| MAs | MA(5) : | 0.89 |
MA(20) : | 0.99 |
| MA(100) : | 1.25 |
MA(250) : | 3.33 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 28.9 |
D(3) : | 20.6 |
| RSI | RSI(14): 46 |
|||
| 52-week | High : | 12.22 | Low : | 0.74 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TPST ] has closed above bottom band by 35.2%. Bollinger Bands are 24% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.08 - 1.09 | 1.09 - 1.09 |
| Low: | 0.84 - 0.84 | 0.84 - 0.85 |
| Close: | 0.88 - 0.89 | 0.89 - 0.9 |
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
Thu, 17 Sep 2026
TPST Stock Slides As Dilutive Financing Overhang Builds - StocksToTrade
Wed, 16 Sep 2026
Tempest Therapeutics (TPST) Stock Surges Wednesday: What's Driving the Action? - Benzinga
Wed, 16 Sep 2026
TPST Stock Spikes As Tempest Therapeutics Expands In Vivo CAR-T Pipeline - timothysykes.com
Wed, 16 Sep 2026
TPST Stock Spikes As Tempest Therapeutics Bets On In Vivo CAR-T - StocksToTrade
Wed, 16 Sep 2026
TPST Stock Jumps As Tempest Therapeutics Expands CAR-T Pipeline - timothysykes.com
Wed, 16 Sep 2026
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 31.7 (%) |
| Held by Institutions | 29.5 (%) |
| Shares Short | 374 (K) |
| Shares Short P.Month | 318 (K) |
| EPS | -3.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -79.4 % |
| Return on Equity (ttm) | -931.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.25 |
| PEG Ratio | 0 |
| Price to Book value | 14.91 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|